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Abstract
Rationale—Extracellular-signal regulated protein kinase (ERK1/2) is activated by ethanol in 
reward-related brain regions. Accordingly, systemic inhibition of ERK1/2 potentiates ethanol 
reinforcement. However, the brain region(s) that mediate this effect are unknown.
Objective—To pharmacologically inhibit ERK1/2 in the medial prefrontal cortex (PFC), nucleus 
accumbens (NAC) and amygdala (AMY) prior to ethanol or sucrose self-administration, and 
evaluate effects of operant ethanol self-administration on ERK1/2 phosphorylation (pERK1/2).
Methods—Male C57BL/6J mice were trained to lever press on a fixed-ratio-4 schedule of 9% 
ethanol+2% sucrose (ethanol) or 2% sucrose (sucrose) reinforcement. Mice were sacrificed 
immediately after the 30th self-administration session and pERK1/2 immunoreactivity was 
quantified in targeted brain regions. Additional groups of mice were injected with SL 327 (0–1.7 
μg/side) in PFC, NAC or AMY prior to self-administration.
Results—pERK1/2 immunoreactivity was significantly increased by operant ethanol (g/kg=1.21 
g/kg; BAC=54.9 mg/dl) in the PFC, NAC (core and shell), and AMY (central nucleus) as 
compared to sucrose. Microinjection of SL 327 (1.7 μg) into the PFC selectively increased ethanol 
self-administration. Intra-NAC injection of SL 327 had no effect on ethanol- but suppressed 
sucrose-reinforced responding. Intra-AMY microinjection of SL 327 had no effect on either 
ethanol- or sucrose-reinforced responding. Locomotor activity was unaffected under all 
conditions.
Conclusions—Operant ethanol self-administration increases pERK1/2 activation in the PFC, 
NAC and AMY. However, ERK1/2 activity only in the PFC mechanistically regulates ethanol 
self-administration. These data suggest that ethanol-induced activation of ERK1/2 in the PFC is a 
critical pharmacological effect that mediates the reinforcing properties of the drug.
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Introduction
Alcoholism is a progressive, debilitating and widespread threat to public health; about 30% 
of the US population battles chronic and disabling relationships with alcohol throughout 
their lifetime (Grant et al. 2004; Hasin et al. 2007). Given the heterogeneous nature of the 
disorder, it is not surprising that a “one drug fits all” treatment approach has limited 
effectiveness (Clapp 2012; Mann 2004). One strategy for developing effective 
pharmacotherapies is to understand the mechanisms that underlie the positive reinforcing 
effects of ethanol (Grant and Samson 1985; Meisch and Thompson 1973; Samson et al. 
1988). Ethanol self-administration is known to be regulated by a number of neurotransmitter 
(Cannady et al. 2013; Hodge et al. 1993) and neuropeptide (Arolfo et al. 2009; Schroeder et 
al. 2003) receptor systems, and attention has focused on elucidating the downstream cell 
signaling pathways that modulate the reinforcing properties of ethanol (Besheer et al. 2012; 
Cui et al. 2013; Faccidomo et al. 2009; Jeanblanc et al. 2013).
ERK1/2 is a serine-threonine kinase and member of the larger mitogen-activated protein 
kinase (MAPK) family. When phosphorylated, the active form of ERK (pERK1/2) can 
influence many diverse neural processes including induction of transcription factors and 
immediate early genes (Davis et al. 2000; Vanhoutte et al. 1999), modulation of receptor 
insertion, trafficking and signaling (Besnard et al. 2014; Qin et al. 2005) and modifications 
of scaffolding proteins such as PSD-93 to alter dendritic spine density and neural 
transmission (Guo et al. 2012). These widespread consequences of ERK1/2 phosphorylation 
reflect ongoing neuronal plasticity that has been shown to be involved in drug-induced 
plasticity (Adams and Sweatt 2002; Davis et al. 2000; Girault et al. 2007) and might 
contribute to the development of escalated ethanol intake and addiction (Chandler and 
Sutton 2005; Zamora-Martinez and Edwards 2014).
Given that ethanol impairs normal brain function and plasticity, it is not surprising that 
ERK1/2 phosphorylation is altered by both acute and chronic ethanol exposure (Agoglia et 
al. 2015; Goulding et al. 2011; Spanos et al. 2012; Zhu et al. 2013) and during alcohol 
withdrawal (Cui et al. 2011; Pandey et al. 2008; Sanna et al. 2002; Valjent et al. 2001). 
Importantly, pERK1/2 is abundantly expressed in brain regions that modulate the rewarding 
effects of ethanol, including the nucleus accumbens (NAC), amygdala (AMY) and 
prefrontal cortex (PFC), and is up or down regulated after acute ethanol exposure in a sub-
nuclei dependent manner (Ibba et al. 2009; Pandey et al. 2008; Rimondini et al. 2002; Rosas 
et al. 2014; Valjent et al. 2004). For example, an acute injection of 3 g/kg ethanol 
significantly increases ERK1/2 phosphorylation in the shell of the NAC, but decreases 
ERK1/2 phosphorylation in the core of the NAC (Agoglia et al. 2015). Likewise, multi-
directional expression patterns of pERK1/2 are also observed in sub-regions of the amygdala 
after acute ethanol injection (Spanos et al. 2012).
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Pharmacological inhibition of ERK1/2 phosphorylation has been shown to disrupt multiple 
measures of drug (Valjent et al. 2000; Zhai et al. 2008) and ethanol (Besheer et al. 2012; 
Faccidomo et al. 2009; Schroeder et al. 2008) reward including self-administration, 
reinstatement, conditioned place preference and locomotor sensitization. Interestingly, both 
the acquisition and expression of conditioned place preference to ethanol is not disrupted by 
ERK1/2 inhibition suggesting that the specific neural mechanisms that regulate the 
contextual learning that is required for ethanol conditioned place preference may be 
different from those involved in ethanol self-administration and reinforcement (Groblewski 
et al. 2011). Nonetheless, these studies provide converging lines of evidence to support the 
hypothesis that the MAPK/ERK signal transduction pathway is functionally involved in 
ethanol-induced neuronal plasticity and that disruption in this pathway, especially in reward- 
and memory-related brain regions, contribute to the development and persistence of 
addiction, dependence and relapse to alcohol (Radwanska et al. 2007; Self 2004).
Our laboratory has shown that systemic inhibition of ERK1/2, using the MEK inhibitor SL 
327, produces a robust and systematic increase in operant responding for a sweetened 
ethanol solution in C57BL/6J mice (Faccidomo et al. 2009). It is notable that this increase in 
self-administration is specific to ethanol as a reinforcer, and does not generalize to other 
non-drug reinforcers, such as sucrose, or to other MAPK pathways. However, these studies 
do not address the relative contribution of specific brain regions on the alterations in ethanol 
self-administration seen after systemic SL 327 treatment. Given that ethanol can both 
increase and decrease pERK1/2 expression in a regionally-dependent manner, the primary 
objective of this study was to identify key brain regions that are functionally involved in 
MAPK regulation of ethanol reinforcement. To address this question, the present study first 
evaluated the effects of operant ethanol self-administration on pERK1/2 levels in the PFC, 
NAC, and AMY. Second, the MEK inhibitor SL 327 was infused site-specifically in the 
PFC, NAC and AMY immediately prior to self-administration sessions of an ethanol or a 
sucrose only solution to determine if ERK1/2 activity in these brain regions mechanistically 
regulates the positive reinforcing effects of ethanol.
Materials and Methods
Subjects
Subjects were male C57BL/6J mice (n=148) arriving at 10 weeks of age from Jackson 
Laboratory (Bar Harbor, ME). Mice were group-housed in clear, polycarbonate cages lined 
with corn-cob bedding. Each cage was covered by a stainless steel wire lid through which 
Purina rodent chow and water was available ad libitum. The vivarium was maintained on a 
12h:12h reverse light/dark cycle (lights off at 0800) with temperature at 21 ± 1 °C. All 
procedures were approved by the Institutional Animal Care and Use Committee of the 
University of North Carolina at Chapel Hill and animals were cared for in accordance with 
the Guide for the Care and Use of Laboratory Animals (2011).
Ethanol Self-administration Apparatus and Procedure
Self-administration sessions were conducted in 16 operant conditioning chambers (Med 
Associates, St. Albans, VT) that were each housed within a sound-attenuating cubicle 
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equipped with a 28V fan to provide ventilation and mask external noise. Opposite walls of 
the chamber each contained a stainless steel ultra-sensitive retractable lever located directly 
below a cue light. Responding on only one of the levers (the “active” lever) was reinforced. 
Responses on the “inactive” lever were recorded but held no contingencies. A drinking 
trough was located adjacent to the active lever and was connected to a syringe pump. 
Reinforcement delivery was accompanied by a brief illumination of the cue light and pump 
sound, both of which served as secondary cues. Responses during this time (800ms) were 
measured but did not contribute towards the response requirement (time-out period). The 
chamber and pump were connected to an interface and computer that recorded the input and 
behavioral output of each mouse (MED-PC for Windows v.4.1).
One week after arrival, mice were presented with either a 9% Ethanol (v/v) + 2% Sucrose 
(w/v) (ethanol) or 2% Sucrose (w/v) only (sucrose) solution, along with water, in their home 
cage for 2 weeks. This procedure was conducted to familiarize the mice to the reinforcing 
solution. We have found that this procedure generates high levels of ethanol self-
administration that exceed the minimum criteria set for binge drinking by the NIAAA (see 
Faccidomo et al. 2009 for a representative blood alcohol content correlation). A slightly 
sweetened ethanol reinforcing solution was used because this reinforcing solution leads to 
more reliable and consistent intake as compared to unsweetened ethanol. Under these 
experimental conditions, mice consume the entire volume that is delivered and dissociation 
between the lever press and consummatory behavior is not observed.
After 2 weeks of home-cage self-administration, mice were placed into an operant 
conditioning chamber for a 16 hr overnight session during which they performed an operant 
response (lever press) that was reinforced with a delivery of either 9% ethanol + 2% sucrose 
(ethanol) or 2% sucrose only (sucrose) into the drinking trough. The reinforcement volume 
was set at .014ml. To facilitate acquisition of lever pressing, mice were water restricted for 
23 hrs prior to the first 2 overnight sessions. During the first overnight session, mice 
responded on a Fixed-ratio 1 (FR 1) schedule of reinforcement. During the 2nd session, the 
response requirement was increased from FR 1 to FR 2 to FR 4 in increments of 25 (ie: after 
receiving the 25th reinforcement, the response requirement increased to FR 2, etc.). The third 
and subsequent sessions were shortened to 1 hr in duration and the response requirement 
was maintained at FR4. All 1 hr sessions were conducted in the dark, between 0900–1500h, 
6 days/week. At the end of each session, the drinking trough was checked to verify 
consumption of all delivered fluid.
Immunohistochemistry
After the end of the 30th self-administration session, ethanol (n=8) and sucrose (n=8) self-
administering mice in Experiment 1 were deeply anesthetized with pentobarbital (150 
mg/kg) and were intracardially perfused with ice cold phosphate buffered saline (PBS; 
0.1M) followed by 4% paraformaldehyde (PFA). Blood was immediately collected before 
infusion of PBS for analysis of plasma blood alcohol content using an AM1 Alcohol 
Analyzer (Analox, Instruments, Lunenburg, MA). Brains were post-fixed in 
paraformaldehyde for 48 hrs and stored in PBS at 4°C until slicing. Coronal brain sections 
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(40μM) were sliced with a vibratome (Leica VT1000S, Leica Microsystems, Buffalo Grove, 
IL) and were stored at −20°C in cryoprotectant until use.
For measurement of pERK1/2 immunoreactivity a two day protocol was used. Free-floating 
tissue sections were washed with 0.1M PBS before being gently bathed in 1% H2O2 to 
inhibit endogenous peroxidase activity. Antigen retrieval was performed by immersing 
tissue in Citra buffer (1X; Biogenics, Napa, CA) for 30 min at 70°C. Sections were blocked 
with 5% normal goat serum (Vector Labs, Burlingame, CA) in PBS with 0.1% Triton X 
(PBSTx) for 1 hr before incubation with a primary antibody for pERK1/2 (1:400; anti-rabbit 
phospho44/42 MAPK [ERK1/2] antibody, #9102, Cell Signaling Technology, Danvers, 
MA) overnight at 4°C. On day 2, sections were washed in PBSTx and then incubated with a 
goat anti-rabbit secondary antibody for 1 hr at 24°C. Antibody bound pERK1/2 was 
visualized using a DAKO-DAB chromogen (Agilent Technologies, Carpinteria, CA), 
sections were counterstained with Toluidine Blue and were mounted onto slides for analysis.
Quantification of immunopositive pixels and cells was conducted at 20X using a light 
microscope (Olympus CX41, Olympus, Tokyo) connected to a computer which ran 
Bioquant software (Bioquant Life Science Software v.8.40.20; Bioquant Corp, Nashville, 
TN). A digital camera (Regita OEM fast, QImaging, Burnaby, BC) attached to the 
microscope was used to acquire all images. The number of immunoreactive pixels and 
immunopositive cells were measured for the medial prefrontal cortex (AP range: +1.98 to 
+1.70), the core and shell of the nucleus accumbens (AP range: +1.54 to +1.18) and the 
central and basolateral amygdala (AP range: −1.06 to −1.34). 3–6 measurements were taken 
from each mouse for each brain region. All values were divided by the area of each region 
and are analyzed as pixels/mm2 and cells/mm2, respectively. Tissue was coded so the 
experimenter was blind to the treatment conditions during analysis.
Stereotaxic Surgery
After 45 self-administration sessions, mice were anesthetized with a cocktail of ketamine 
(120 mg/kg, i.p.) and xylazine (9 mg/kg, i.p.) and placed into a stereotaxic frame (Kopf 
Instruments, Tujunga, CA). Mice were implanted with a 26 gauge guide cannula (Plastics 
One, Roanoke, VA) unilaterally aimed at either the right or the left medial prefrontal cortex 
(Experiment 2; PFC; AP +1.7mm; ML ±0.4mm; DV −1.2mm, from skull surface), 
bilaterally aimed at the shell of the nucleus accumbens (Experiment 3; NAC; AP= −1.42 
and ML= +/−0.6 from bregma, DV= −2.9 mm from dura), or bilaterally aimed at the central 
amygdala (Experiment 4; AMY; AP= −1.22 and ML= +/−2.5 from bregma, DV= 3.25 mm 
from dura). All coordinates were calculated according to the atlas of (Franklin and Paxinos 
2001). The guide cannula was secured to the skull with dental cement (Durelon, Butler 
Schein, Dublin, OH) and a 33 gauge obturator (Plastics One) was inserted after surgery and 
was moved daily to prevent blockage and scarring. An aversive tasting polish (Bite It©) 
coated the head-mount and obturator to prevent damage by cage-mates. Mice were 
monitored until they woke up from anesthesia, after which they were returned to the animal 
vivarium. Mice recovered from surgery for 1 week before resuming ethanol or sucrose self-
administration. A minority of mice (n=12) did not recover from anesthesia or were sick after 
surgery.
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Sham injections (insertion of the injector and activation of the pump, but no drug delivery) 
began once stable levels of operant responding were observed after surgery (obtaining >10 
reinforcements/session in 3 consecutive sessions). Sham injections were repeated until each 
mouse responded stably after injection (ca. 3–5 sham injections). Next, dose-effect curves 
for the MEK inhibitor, SL 327, were conducted for all three brain regions and for each 
reinforcing solution (6 experimental groups). Vehicle and SL 327 (0.3, 1.0 and 1.7 μg/side) 
were injected in a counterbalanced design, with a minimum of 3 self-administration sessions 
separating each test day. Drug solutions were bilaterally infused (0.5 μl/side) over a 4 min 
period (0.125μl/min/side) using a 1 μl Hamilton syringe connected to a Harvard Apparatus 
pump (Holliston, MA). A 33 gauge injector (Plastics One) extended 2mm beyond the tip of 
the guide cannula and remained in place for 1 min after the infusion ended to facilitate drug 
diffusion and to minimize vertical capillary action along the injection tract. Mice were 
unrestrained during the infusion and were placed immediately into the operant conditioning 
chamber for a 1 hr session.
Immediately after the final microinjection, mice were deeply anesthetized with sodium 
pentobarbital and were intracardially perfused with PBS and PFA. For histological 
verification, brains were sliced into 50 μm coronal sections and were stained with cresyl 
violet to visualize the injection site (Figures 1–3, Panels A&B). Subjects with missed 
cannula placements (n=17), a lost headmount (n=1) and clogged cannula (n=28) were 
excluded from the final analysis. Unfortunately, a significant minority of subjects in 
experiments 2 and 3 had clogged cannula due to the requirement that both bilateral cannula 
be viable and to the slightly sticky nature of the DMSO vehicle.
Microinjections & Locomotor Activity
Open field activity was measured in Plexiglas activity monitor chambers (27.9 cm2; 
ENV-510, Med Associates). Two sets of 16 pulse-modulated infrared photobeams recorded 
X-Y ambulatory movements. The mouse’s position in the open field was assessed every 
100ms to quantify the distance traveled (cm) throughout the session. Each activity monitor 
was connected to a computer that compiled all data.
Initially, mice (n=35) were allowed to habituate to the open field apparatus for 2 hrs. One 
week later, mice with a history of ethanol or sucrose self-administration that did not exhibit 
stable rates of responding after surgery were given a sham injection prior to being placed in 
the open field for 1 hr. Vehicle or SL 327 (1.0 and 1.7 μg/side) were injected in a 
counterbalanced design, with a minimum of 1 week separating each test.
Drugs
All ethanol solutions (v/v) were prepared by diluting 95% ethanol (Pharmco Products Inc.; 
Brookfield, CT) with water. The MEK inhibitor, SL 327 (α-[Amino[(4-
aminophenyl)thio]methylene]-2-(trifluoromethyl)benzeneacetonitrile; Tocris Bioscience; 
Ellisville, MO) was dissolved in 100% DMSO (dimethlysulfoxide, Mallinckrodt Baker, Inc.; 
Phillipsburg, NJ) and was diluted to 15% DMSO solution with distilled water.
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To assess differences in baseline levels of acquisition of ethanol or sucrose self-
administration, a t-test was conducted on the average number of reinforcements obtained in 
a 1 hr session between ethanol and sucrose self-administering mice for each brain region. 
For brain region and reinforcing solution, a 2 way repeated measure mixed ANOVA (RM 
ANOVA) was conducted (DOSE x TIME) on cumulative number of active lever presses and 
dose consumed (g/kg), respectively. A secondary analysis was conducted to compare the 
efficacy of SL 327 on the 1st vs 2nd half of the drinking session by collapsing consummatory 
measures into 2, 30 min bins (0–30 min vs. 31–60 min). A one way RM ANOVA was 
conducted (DOSE) for this analysis. Locomotor activity was analyzed using one-way RM 
ANOVA’s for each group on total distance traveled in 1hr. Immunohistochemical data was 
analyzed separately for each subregion using a t-test to compare ethanol and sucrose self-
administering groups. When appropriate, all post-hoc analyses were conducted using 
Dunnett’s test with the vehicle condition as the common control. α was set at 0.05 for all 
comparisons.
Results
Experiment 1: Effect of operant ethanol self-administration on pERK1/2 immunoreactivity
All mice demonstrated stable and comparable levels of ethanol and sucrose self-
administration in a 1 hr self-administration session. The average number of reinforcements 
averaged across 30 drinking sessions did not significantly differ between groups (27.8 ± 3.2 
for ethanol and 28.3 ± 4.2 for sucrose self-administering mice) and the average number of 
reinforcements immediately prior to intracardial perfusion was 30.8 ± 4.9 and 35.4 ± 10.0, 
respectively. The average dose consumed and BAC at the final operant self-administration 
session was 1.21 g/kg and 54.9 mg/dl, respectively.
Overall, this experiment revealed that 30 sessions of operant responding for moderate 
amounts of ethanol induced significant increases in pERK1/2 immunoreactive pixels and 
cells in most of the regions that were investigated relative to sucrose self-administering 
mice. Specifically, in the medial prefrontal cortex, mice with a history of operant ethanol 
self-administration had significantly increased levels of immunoreactive cells (t(11) = 2.140, 
p=0.0278) and pixels for pERK1/2 (t(11) = 2.646, p=0.0114, Figure 1A) as compared to 
sucrose self-administering mice. Levels of pERK1/2 immunoreactive cells and pixels were 
significantly higher in both the core (cells: t(13) = 1.935, p=0.038; pixels: t(13) = 1.928, 
p=0.038, Figure 1B) and shell (cells: t(14) = 1.74, p=0.051; pixels: t(14) = 2.035, p=0.030, 
Figure 1B) of the nucleus accumbens in ethanol but not sucrose self-administering mice. In 
the amygdala, there was a differential effect between the two sub-regions that were 
analyzed. Namely, an increase in pERK1/2 immunoreactive pixels and cells was found in 
the CeA (cells: t(14) = 2.976, p=0.005; pixels: t(14) = 2.797, p=0.007, Figure 1C) but not in 
the BLA.
Experiment 2: ERK1/2 inhibition in the prefrontal cortex
All mice demonstrated stable and comparable levels of ethanol and sucrose self-
administration in a 1 hr self-administration session. Across all experiments, the drinking 
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troughs were empty at the end of the session. The average number of reinforcements 
averaged across 45 drinking sessions did not significantly differ between groups (23.0 ± 2.2 
for ethanol+sucrose and 27.2 ± 2.9 for sucrose self-administering mice). Histological 
analysis showed that n=32 mice received injections into the PFC (Figure 2A–B)
Intra-PFC microinjection of SL 327 produced a robust increase in ethanol self-
administration but a decrease in sucrose self-administration. Both drug effects were 
independent from concomitant locomotor-impairing effects and the pharmacological effect 
of SL 327 did not differ according to the side the cannula was placed in. Specifically, there 
was a significant main effect of time (Figure 2C; F(11,198) = 31.4, p < 0.001) and of SL 327 
dose (Figure 2C; F(3,198) = 4.0, p=0.023) on the number of active lever presses in ethanol 
self-administering mice. Post-hoc tests revealed that the highest dose of SL 327 (1.7μg) 
significantly increased active lever responding. Similarly, there was a significant main effect 
of time (F(11,198) = 31.6, p < 0.001) and of SL 327 dose (F(3,198) = 3.9, p=0.026) on the total 
dose consumed (g/kg) during the session. Post-hoc tests revealed that a higher g/kg was 
obtained after intra-PFC administration of 1.7μg of SL 327 as compared to vehicle (0.92 ± .
11 vs. 0.69 ± .11 g/kg/hr). Responding on the inactive lever was not affected by treatment 
condition. Given the significant main effect of time and to more specifically address the 
temporal effect of SL 327 on operant responding, data were collapsed into two 30 min bins 
and were analyzed independently (Figure 2D–E). A significant main effect of SL 327 dose 
was found within the first 30 min after infusion of the drug (F(3,21) = 3.7, p=0.028; Figure 
2D). A post-hoc test revealed that this main effect was due to a significant increase in 
operant responding for ethanol after infusion of 1.7μg SL 327. This drug effect was no 
longer present in the 2nd half of the self-administration session (Figure 2E).
In sucrose self-administering mice, there was a significant main effect of time (Figure 2F; 
F(11,198) = 34.4, p < 0.001), as well as a significant interaction between time and SL 327 
dose (Figure 2F; F(33,198) = 2.66, p < 0.001) on the number of active lever presses obtained. 
Post-hoc tests revealed that intra-PFC administration of 0.3 and 1.7μg of SL 327 
significantly decreased active lever responding by minute 45 of the session and that all doses 
significantly decreased operant responding for sucrose during the last 15 min of the drinking 
session. Responding on the inactive lever was not affected by treatment condition. When 
data were collapsed into two 30 min bins and analyzed independently, a one way RM 
ANOVA revealed a significant main effect of SL 327 dose in the 2nd half of the session, 
during min 31–60 (F(3,21) = 3.7, p=0.028; Figure 2H). A post-hoc test revealed that this main 
effect was due to a significant decrease in operant responding for sucrose after infusion of 
1.7μg SL 327. In contrast to ethanol self-administering mice, this drug effect was not present 
in the 1nd half of the self-administration session (Figure 2G).
Mice that did not lever press consistently after surgery or after sham injections (n=15) were 
used to test whether SL327 altered spontaneous locomotor activity. They were first 
habituated to the locomotor chambers and subsequently, placed into the chambers for 1 hr 
sessions following a microinjection of vehicle or SL 327. During the 2 hr habituation 
session, mice moved, on average, 20,824 ± 1024 cm/2hrs. Distance traveled after vehicle 
injection did not differ between groups and intra-PFC microinjection of SL 327 did not 
affect spontaneous locomotor activity (Table 1).
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Experiment 3: ERK1/2 inhibition in the nucleus accumbens
All mice demonstrated stable and comparable levels of ethanol and sucrose self-
administration in a 1 hr self-administration session. The average number of reinforcements 
averaged across 45 drinking sessions did not significantly differ between groups (29.1 ± 3.2 
for ethanol and 33.8 ± 4.9 for sucrose self-administering mice). Histological analysis 
showed that n=22 mice received injections predominantly into the shell region of the NAC 
(Figure 3A–B).
Unlike results observed in the PFC, SL 327 infusion into the NAC did not significantly alter 
operant responding for ethanol throughout the 1 hr session (Figure 3C–E). The average dose 
consumed after intra-NAC microinjection of vehicle was 0.73 ± .15 g/kg/hr and was 
insensitive to intra-NAC microinjection of SL 327. Likewise, responding on the inactive 
lever was not affected by treatment condition.
In contrast, sucrose self-administration showed a significant main effect of time (Figure 3F; 
F(11,176) = 25.8, p < 0.001), dose (Figure 3F; F(11,176) = 12.3, p < 0.001), and a significant 
interaction of TIME x DOSE (Figure 3F; F(22,176) = 7.5, p < 0.001) on the number of active 
lever presses. Post-hoc tests revealed that intra-PFC administration of both doses of SL 327 
(1.0 μg and 1.7μg) significantly decreased active lever responding. Moreover, the reduction 
of responding elicited by intra-NAC microinjection of 1.7μg of SL 327 emerged 15 min into 
the self-administration session and the effects of 1.0μg of SL 327 emerged by 30 min 
(Figure 3G–H). Likewise, inactive lever responding was also reduced by intra-NAC 
injection of SL 327. For this behavior, there was a significant main effect of time (F(11,176) = 
10.3, p < 0.001) and a significant interaction of TIME x DOSE (F(22,176) = 3.7, p < 0.001). 
Post-hoc tests revealed that intra-PFC administration of 1.0 μg and 1.7 μg of SL 327 
significantly decreased active lever responding and that this effect emerged 50 min into the 
self-administration session. When data were collapsed into two 30 min bins and analyzed 
independently, a one way RM ANOVA revealed a significant main effect of SL 327 dose 
during min 0–30 (F(2,12) = 6.3, p=0.013; Figure 3H) and during min 31–60 (F(2,12) = 7.6, 
p=0.007; Figure 3H). For both time bins, this effect was due to a significant reduction in 
operant responding for sucrose after infusion of both doses of SL 327.
Mice that did not lever press consistently after surgery or after sham injections (n=10) were 
used to test whether SL327 altered spontaneous locomotor activity. They were first 
habituated to the locomotor chambers and subsequently, placed into the chambers for 1 hr 
sessions following a microinjection of vehicle or SL 327. During the 2 hr habituation 
session, mice moved, on average, 11,776 ± 1557 cm/2hrs. Activity levels after vehicle 
injection did not differ between ethanol and sucrose groups and were unaffected by SL 327 
administration (Table 1).
Experiment 4: ERK1/2 inhibition in the amygdala
All mice demonstrated stable and comparable levels of ethanol and sucrose self-
administration in a 1 hr self-administration session. The average number of reinforcements 
averaged across 45 drinking sessions did not significantly differ between groups (26.6 ± 4.7 
for ethanol and 18.3 ± 2.5 for sucrose self-administering mice). Histological analysis 
Faccidomo et al. Page 9













showed that the majority of mice received injections aimed at the central nucleus of the 
amygdala though some injections occurred in the basolateral amygdala (n=22; Figure 4A–
B).
Although there was a trend for increased self-administration after drug microinjection, 
overall, intra-amygdala microinjection of SL 327 did not significantly modulate either 
ethanol or sucrose self-administration. Specifically, there was a significant main effect of 
time, but not of dose, on the number of active lever presses (Figure 4C–E; F(11,132) = 47.4, p 
< 0.001) in ethanol self-administering mice. The average dose consumed (g/kg) after intra-
amygdala microinjection of vehicle was 0.63 ± .16 g/kg/hr and was not affected by intra-
amygdala microinjection of SL 327. Additionally, responding on the inactive lever was not 
affected by treatment condition.
Likewise, sucrose self-administering mice also showed a significant main effect of time 
(Figure 4F–H; F(11,198) = 32.0, p < 0.001), but not of dose, on the number of cumulative 
active lever presses obtained. This effect was selective to the active lever as inactive 
responding was unaffected by treatment condition.
Mice that did not lever press consistently after surgery or after sham injections (n=10) were 
used to test whether SL327 altered spontaneous locomotor activity. They were first 
habituated to the locomotor chambers and subsequently, placed into the chambers for 1 hr 
sessions following a microinjection of vehicle or SL 327. During the 2 hr habituation 
session, mice moved, on average, 19,723 ± 953 cm/2hrs. Distance traveled after vehicle 
injection did not differ between groups and were unaffected by SL 327 microinjection 
(Table 1).
Discussion
Repeated drug use produces neuroadaptive changes in molecular and cell signaling 
pathways that, in turn, lead to long-lasting neural and behavioral pathologies that 
characterize addiction (Nestler 2001). Among these cellular systems, the activity-dependent 
MAPK pathway is crucial for the transduction of neuronal activity into immediate or 
enduring changes in neural plasticity and is critical in addiction (Girault et al. 2007; Thomas 
and Huganir 2004). The present work extends and refines the functional role of ERK/MAPK 
in the direct regulation of the positive reinforcing effects of ethanol (Faccidomo et al. 2009). 
Results from this study first demonstrate that the positive reinforcing effects of ethanol are 
associated with increased activation of ERK1/2 in the PFC, NAC and AMY. These 
immunohistochemical data confirm prior studies showing that acute ethanol administration 
(Agoglia et al. 2015; Ibba et al. 2009; Rosas et al. 2014; Spanos et al. 2012; Valjent et al. 
2004) and chronic ethanol intake (Pandey et al. 2008; Zhu et al. 2013) can up- or down-
regulate levels of pERK1/2 in a brain region-dependent manner. The present findings extend 
this research by showing that operant self-administration of moderate doses of ethanol 
robustly increases pERK1/2 immumoreactivity above what is engendered by the non-drug 
reinforcer, sucrose. Here we also sought to determine if ERK activity in the PFC, NAC, or 
AMY mechanistically regulates operant alcohol self-administration. Results show that site-
specific infusion of the MEK/ERK inhibitor SL 327 potentiated ethanol self-administration 
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only when this drug was infused into the PFC. These data are the first direct evidence to 
show that ERK1/2 activity in the prefrontal cortex is functionally regulates the positive 
reinforcing properties of ethanol.
Although the specific mechanisms by which self-administered ethanol increased pERK1/2 
immunoreactivity in the PFC, NAC, and AMY remain to be determined, several well-
characterized biochemical effects of ethanol may contribute to this process. For instance, 
ERK1/2 phosphorylation requires the coordinated activation of dopamine D1-like and 
NMDA receptors (Shiflett and Balleine 2011). Ethanol increases dopamine levels in the 
NAC (Di Chiara and Imperato 1986; Olive et al. 2000) and PFC (Schier et al. 2013), and 
elevates glutamate levels in the NAC (Ding et al. 2013; Griffin et al. 2014; Szumlinski et al. 
2007) and AMY (Roberto et al. 2004). Moreover, ethanol activates ERK1/2 via a D1-
dependent mechanism in NAC and AMY (Ibba et al. 2009). Thus, it is plausible that self-
administered ethanol produces a coordinated increase in dopamine and glutamate levels in 
mesocorticolimbic brain regions that leads to downstream ERK1/2 activation.
A highly significant finding from this study is that ERK1/2 phosphorylation in the PFC is a 
molecular target of self-administered ethanol that, in turn, mechanistically regulates the 
positive reinforcing effects of the drug. We previously discovered that the PFC actively 
regulates behavioral plasticity in addiction by modulating the positive reinforcing effects of 
ethanol (Hodge et al. 1996) and that ethanol increases ERK1/2 phosphorylation in the PFC 
(Spanos et al. 2012). In this study, pharmacological inhibition of ERK1/2 activity in the PFC 
via local infusion of the MEK inhibitor SL 327 produced a significant increase in ethanol 
reinforced responding in the absence of non-specific motor effects, which is consistent with 
prior evidence indicating that systemic ERK1/2 inhibition produces the same behavioral 
effect (Faccidomo et al. 2009). Results also showed that operant self-administration of 
relatively low doses of ethanol (1.21 g/kg; BAC = 54.9 mg/dl) significantly increased 
pERK1/2 phosphorylation in the PFC. Thus, we hypothesize that SL 327 infusion in the 
PFC increased the reinforcing effects of ethanol because it inhibited a critical molecular 
consequence of ethanol-self administration – e.g., increased pERK1/2 activity. Thus, the 
increased rate of ethanol self-administration may reflect a form of behavioral compensation 
to overcome this pharmacological “antagonism” of ethanol-induced ERK1/2 activity by 
MEK inhibition in the PFC. Similarly, inhibition of ERK1/2 signaling in the PFC may have 
escalated ethanol self-administration via altered function of PFC-linked neural circuits, 
affecting downstream components of the mesocorticolimbic system. For example, ERK1/2 
inhibition in PFC may inhibit excitatory glutamatergic projections that terminate in the NAC 
(Berendse et al. 1992) where glutamate transmission promotes increased alcohol drinking 
(Griffin et al. 2014; Kapasova and Szumlinski 2008) and is required for the positive 
reinforcing (Besheer et al. 2010) and discriminative stimulus (Besheer et al. 2009) effects of 
ethanol. Moreover, dysregulated PFC to NAC glutamate transmission may drive increased 
motivation to seek a variety of drugs (Kalivas et al. 2005). Overall, these findings indicate 
that ERK1/2 signaling in the PFC modulates the positive reinforcing properties of ethanol, 
which suggests that this pathway may influence the development of addiction (Wise and 
Koob 2014).
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Unlike in the PFC, pharmacological inhibition of ERK1/2 activity in the NAC and AMY did 
not affect ethanol reinforced responding. However, responding for sucrose was significantly 
blunted by both doses of SL 327, beginning 15 min after microinfusion into the NAC and 
persisting throughout the self-administration session. This result supports the hypothesis that 
under these experimental conditions, inhibition of the ERK1/2 pathway in the NAC appears 
to mediate processes involved in regulating the motivation for non-drug rewards. The NAC 
is activated in response to both appetitive and drug stimuli that are rewarding and many labs 
have indeed demonstrated that the NAC dynamically regulates the motivation for multiple 
types of goal-directed behaviors (Bassareo et al. 2011; Di Chiara and Bassareo 2007). It is 
also evident that sub-populations of neurons within this region distinctly respond to different 
types of reinforcers (i.e. ethanol vs. water vs. sucrose; (Bassareo et al. 2011; Carelli et al. 
2000; Carelli and Wondolowski 2006; Robinson and Carelli 2008; Roop et al. 2002). 
Although we were unable to differentially target distinct populations of neurons, our results 
suggest that NAC neurons that respond to non-drug rewards such as sucrose may utilize 
ERK1/2 cell signaling in the dynamic regulation of motivated behavior for non-drug 
rewards.
Food restriction can enhance both the behavioral and central reinforcing effects of drugs of 
abuse by increasing mesolimbic DA signaling and consequently, the salience of the 
rewarding substance (Cabeza de Vaca and Carr 1998; Carr 2002; Carr et al. 2001; Carroll et 
al. 1979). ERK1/2 is a downstream molecular target of D1 receptors in the NAC and this 
kinase is elevated in food-restricted rats, both at baseline and after injection with a D1 
receptor agonist or cocaine (Haberny et al. 2004; Liu et al. 2011). Importantly, acute 
ethanol-induced increase in pERK1/2 can be blocked by pretreatment with a D1 receptor 
antagonist (Ibba et al. 2009) and pharmacological inhibition of ERK1/2 in the nucleus 
accumbens by SL 327 does not alter baseline self-stimulation threshold and is not rewarding 
(Carr et al. 2009). Moreover, intra-VTA infusion of the MEK inhibitor U0126 does not alter 
ethanol–reinforced responding in highly trained rats suggesting that ERK regulation along 
the mesolimbic dopaminergic pathway is not directly regulating ethanol reinforcement 
(Carnicella et al. 2008). Taken together with our findings, these data suggest that the D1-
ERK intracellular signaling cascade in the nucleus accumbens is resistant to manipulation by 
SL 327 but sensitive to pharmacological blockade of postsynaptic dopamine receptors. Thus, 
a possible explanation for the absence of an effect of intra-NAC ERK inhibition on ethanol 
reinforcment is that once the association between the reinforcer and the behavior is learned, 
accumbal DA is no longer required for the behavior to occur and the D1-ERK cascade in the 
accumbens is no longer engaged. A second possible consequence to repeated alcohol 
exposure is tolerance to the ethanol-induced increase in ERK1/2 activation. However, 
Spanos et al. (2012) and Agoglia et al. (2015) show that acute ethanol increases pERK1/2 
immunoreactivity in the NAC and the data from Experiment 4 show a similar effect after 
chronic self-administration of sweetened ethanol. Thus, under the current conditions, 
tolerance to ethanol-induced ERK1/2 activation in this region was not observed. An 
interesting future experiment would be to inhibit ERK1/2 in this pathway during the early 
acquisition of operant responding for ethanol in untrained animals to determine if this 
signaling pathway in the nucleus accumbens might be more influential during the 
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development of the learned relationship between the behavioral response (lever press) and 
the reinforcer (ethanol).
Notably, while all groups had similar rates of responding during the acquisition phase of 
training (ie: the average number of reinforcements for ethanol and sucrose mice did not 
differ), rates of responding declined after intra-AMY infusion of vehicle in both groups. It is 
likely that these mice were sensitive to the extra handling required for these microinjection 
studies given that 2 separate injectors were bilaterally inserted into this region. Importantly, 
despite the decrease in response rate in the amygdala cohorts, there was not a significant 
difference between ethanol- and sucrose-reinforced responses after vehicle microinjection. 
Thus, it is unlikely that the decrease in response rate impacted the effect of SL 327 on 
responding since these were within-subject experiments. Given the absence of difference in 
response rates within experiments between ethanol and sucrose mice, it also does not seem 
likely that caloric differences in the consumed reinforcing solution between ethanol and 
sucrose groups (approximately 0.172 and 0.022 calories, respectively) accounted for the 
differences in drug effects. Their food contains 4.1 cal/gram and each mouse eats on average 
20 cal/day. Thus, the number of calories that are contributing to the diet from both the 2% 
sucrose and 2% sucrose/9% ethanol solution is <1% of total daily intake and as such, it is 
highly unlikely that these caloric differences in the reinforcing solutions are sufficient to 
alter the pharmacological effects of SL 327.
The ERK/MAPK pathway in the central nucleus of the amygdala (CeA) is activated in 
response to acute ethanol injection and home cage 24-h and binge 4-h self-administration, 
(Ibba et al. 2009; Spanos et al. 2012; Thorsell et al. 2013). Likewise, we found that 30 days 
of operant ethanol self-administration significantly increased pERK1/2 IHC in the CeA but 
not BLA (Figure 1C). Together, these data show that ethanol-induced activation of pERK1/2 
in the CeA is a strikingly robust and consistent molecular response to ethanol that occurs via 
multiple routes, schedules and methods of ethanol self-administration. Thus, the 
pharmacological results from experiment 3 are somewhat difficult to interpret as ERK1/2 
inhibition in the amygdala did not modulate ethanol or sucrose reinforced responding. 
Others have shown that dampening activity in the central and medial amygdala promotes 
home cage drinking (Pandey et al. 2006), perhaps due to enhancement of an anxiogenic 
state. However, this effect is restricted to the medial and central amygdala where basal 
ERK1/2 levels are elevated as a consequence of ethanol drinking. Given the physical 
limitations of our microinjections, it was not possible in this study to selectively inhibit 
ERK1/2 in the central and medial vs. the basolateral amygdala although we would predict 
that selectively inhibition of ERK1/2 in only CeA neurons would produce an increase in 
ethanol self-administration. An alternative explanation is that under these conditions, 
ERK1/2 activity in the amygdala is less involved in modulating reinforcement and more 
involved in regulating cue-induced reinstatement of drug-seeking, or relapse-like behavior, 
rather than drug self-administration. For instance, pERK1/2 immunoreactivity in the BLA 
and CeA are upregulated in abstinent animals after exposure to ethanol and cocaine-
associated cues suggesting that these sub-nuclei are dynamically activated by salient drug 
cues and may be more involved in modulating drug-seeking rather than drug-taking (Lu et 
al. 2005; Radwanska et al. 2007; Schroeder et al. 2008). Moreover, pretreatment with the 
glutamatergic antagonists, MPEP and AP-5, as well as the MEK inhibitor, U0126, blocks 
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both the cue-associated activation of pERK1/2 and responding on the active lever during a 
reinstatement session, indicating that cue-induced reinstatement may be mediated by both 
glutamate and ERK1/2 activity. Thus, the present study may have failed to find evidence for 
functional involvement of the ERK1/2 activity in the amygdala in ethanol-reinforced 
responding because ERK1/2 in this region may regulate cue-induced drug-seeking, or 
relapse-like, behavior rather than primary reinforcement or drug-taking behavior.
Collectively, the most salient finding from these studies is that a history of ethanol self-
administration induces an increase in ERK1/2 phosphorylation in multiple reward-relevant 
brain regions yet inhibition of ERK1/2 activity only in the PFC preferentially increases 
operant responding for ethanol (Table 2). Given that acute ethanol leads to a transient 
increase in pERK1/2 expression in reward-related brain regions, it is likely that 
pharmacological blockade of ERK1/2 phosphorylation is inhibiting ethanol-induced ERK1/2 
phosphorylation which is promoting escalated operant responding and ethanol self-
administration in a compensatory manner. Though we cannot definitively resolve why a 
similar functional relationship did not emerge in the amygdala and nucleus accumbens, we 
can speculate that the lack of subnuclei selectivity with our injections may have masked a 
functional effect of the inhibitor on reinforcing properties of ethanol in these regions. In 
conclusion, it is evident that the PFC is the key region that underlies ERK’s modulation of 
the positive reinforcing effects of ethanol self-administration in a mouse model of ethanol 
self-administration.
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Figure 1. Effect of operant ethanol self-administration on pERK1/2 immunoreactivity
(A–C) White bars represent the mean number of immunoreactive pixels/mm2 for pERK1/2 
in tissue taken from mice that self-administered sucrose. Black bars represent the mean 
number of immunoreactive pixels/mm2 for pERK1/2 in tissue taken from mice that self-
administered ethanol. Vertical lines represent the SEM for all conditions and asterisks 
denote significance as compared to sucrose (P<0.05). Atlas plates adapted from Franklin and 
Paxinos show the anatomical areas that were analyzed (outlined in black) and representative 
images of the pERK1/2 immunohistochemistry are shown on the right.
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Figure 2. ERK1/2 inhibition in the prefrontal cortex
(A) A schematic representation of the mouse PFC showing A-P distance from Bregma. 
Filled circles indicate the approximate ventral tip of the injection site for each mouse. (B) A 
representative photomicrograph (2X) of a coronal brain section with a visible injection site 
(black arrow). (C&F) White circles represent the cumulative number ethanol or sucrose 
reinforced active lever presses after vehicle infusion. Grey symbols represent the effect of 
SL 327 on operant responding for ethanol or sucrose. (D–E&G–H) The white vertical bars 
represent the average number of responses after a vehicle microinjection and the grey 
vertical bars represent the average number of responses after SL 327 microinjection. In all 
panels, data are presented as mean (symbols or vertical bars) ± SEM (vertical lines) and 
asterisks denote significance as compared to vehicle (P<0.05).
Faccidomo et al. Page 20













Figure 3. ERK1/2 inhibition in the nucleus accumbens
(A) A schematic representation of the mouse NAC showing A-P distance from Bregma. 
Filled circles indicate the approximate ventral tip of the injection site for each mouse. (B) A 
representative photomicrograph (2X) of a coronal brain section with a visible injection site 
(black arrow). (C&F) White circles represent the cumulative number ethanol or sucrose 
reinforced active lever presses after vehicle infusion. Grey symbols represent the effect of 
SL 327 on operant responding for ethanol or sucrose. (D–E&G–H) The white vertical bars 
represent the average number of responses after a vehicle microinjection and the grey 
vertical bars represent the average number of responses after SL 327 microinjection. In all 
panels, data are presented as mean (symbols or vertical bars) ± SEM (vertical lines) and 
asterisks denote significance as compared to vehicle (P<0.05).
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Figure 4. ERK1/2 inhibition in the amygdala
(A) A schematic representation of the mouse AMY showing A-P distance from Bregma. 
Filled circles indicate the approximate ventral tip of the injection site for each mouse. (B) A 
representative photomicrograph (2X) of a coronal brain section with a visible injection site 
(black arrow). (C&F) White circles represent the cumulative number ethanol or sucrose 
reinforced active lever presses after vehicle infusion. Grey symbols represent the effect of 
SL 327 on operant responding for ethanol or sucrose. (D–E&G–H) The white vertical bars 
represent the average number of responses after a vehicle microinjection and the grey 
vertical bars represent the average number of responses after SL 327 microinjection. In all 
panels, data are presented as mean (symbols or vertical bars) ± SEM (vertical lines).
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Table 1
Effect of SL 327 on open field locomotor activity (1 hr session)
PREFRONTAL CORTEX ETHANOL DRINKERS SUCROSE DRINKERS
 Vehicle 5922 ± 948 6106 ± 1382
 1.0 μg SL 327 6751 ± 932 6307 ± 970
 1.7 μg SL 327 5915 ± 727 6252 ± 1615
AMYGDALA ETHANOL DRINKERS SUCROSE DRINKERS
 Vehicle 5922 ± 948 6106 ± 1382
 1.0 μg SL 327 6751 ± 932 6307 ± 970
 1.7μg SL 327 5915 ± 727 6252 ± 1615
NUCLEUS ACCUMBENS ETHANOL DRINKERS SUCROSE DRINKERS
 Vehicle 6986 ± 2324 6709 ± 512
 1.0 μg SL 327 6722 ± 2084 6817 ± 683
 1.7μg SL 327 7674 ± 3198 6911 ± 1155
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